Loading
The prospective Vietnamese study of about 9,000 people without symptoms that measured how the SPOT-MAS blood test performs in screening.
K-DETEK (NCT05227261) is an observational study sponsored by Gene Solutions with Medical University of Ho Chi Minh City, Hanoi Medical University, Hanoi Oncology Hospital and others. Its primary objective was the performance of the cell-free DNA test in detecting cancer early, with the accuracy of its predicted tissue of origin against imaging as a secondary objective. Results were published in BMC Medicine in 2025: 43 of 9,024 tested positive and 17 had cancer.
The registry record, read on 29 October 2026, gives its status as completed, with 9,057 participants enrolled, a start on 10 April 2022 and primary completion on 10 April 2023.
Shares Gene Solutions, SPOT-MAS, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Gene Solutions, SPOT-MAS, Multi-cancer early detection (MCED).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/